Celebrating 15 years of the Injectable Device Development Summit
Enable Advanced Delivery of Complex Biologics, Optimize Patient-Centric Device Design & Accelerate Combination Product Development
The drug delivery landscape is evolving rapidly, with micro moulding driving evolving trends in self-injection devices and increasing drive towards sustainability. At the same time, sweeping regulatory shifts are reshaping the future of combination product development, as U.S. policy accelerates domestic drug approvals and heightens oversight of global manufacturing practices.
Built for device innovators by industry pioneers, the 15th Injectable Device Development Summit will unite 70+ senior leaders from pharma, biotech, and device service providers including Eli Lilly, Takeda, Sanofi, and Merck, to unpack how to enable flexible, patient-centric delivery platforms for high-viscosity, large-volume formulations. From advancing platform strategies to de-risking regulatory pathways and improving real-world usability, this is your essential forum to drive forward next-generation delivery systems that meet the needs of both regulators and patients.
This event is FREE* to attend for drug developers to support delivery innovation and product development while connecting you with expert partners to find the right device solutions.
What’s New for 2025?
- Overcome delivery challenges of large-volume biologics by aligning formulation, device innovation, and risk strategies to ensure safe, patient-friendly solution.
- Accelerate device submissions by leveraging platform strategies, optimizing resources, and balancing portfolio priorities for faster, scalable development.
- Improve product safety by embedding patient-centric design into risk management and device selection, ensuring delivery solutions meet real-world user needs.
- Streamline injectable device supply chains by selecting fully integrated partners that reduce risk, minimize delays, and support scalable, end-to-end development.
Your 2025 Speaker Faculty Includes:
Lisa Ray
Executive Director; Portfolio & Operations, Delivery, Device & Connected Solutions
Eli Lilly & Co.
Who Attended Last Year?
Access the 2025 Agenda
2025 Partners Include:
